We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Anixa Biosciences Inc (ANIX) NPV

Sell:$2.81 Buy:$3.35 Change: $0.03 (1.03%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
Change: $0.03 (1.03%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
Change: $0.03 (1.03%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins.

Contact details

3150 Almaden Expy Ste 250
United States
+1 (408) 7089808

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$100.82 million
Shares in issue:
32.01 million
United States
US dollar

Key personnel

  • Amit Kumar
    Chairman of the Board, Chief Executive Officer
  • Michael Catelani
    President, Chief Financial Officer, Chief Operating Officer, Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.